Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$62.8 million.

  • NewAmsterdam Pharma Co N.V's Cash from Investing Activities rose 3441.33% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$216.0 million, marking a year-over-year decrease of 32036.01%. This contributed to the annual value of -$62.8 million for FY2024, which is 261766.67% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Cash from Investing Activities stood at -$62.8 million, which was down 261,766.67% from -$24,000 recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Cash from Investing Activities ranged from a high of -$14,843 in FY2020 and a low of -$62.8 million during FY2024.
  • Its 3-year average for Cash from Investing Activities is -$21.0 million, with a median of -$221,000 in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 89.14% in 2023, then slumped by 261,766.67% in 2024.
  • NewAmsterdam Pharma Co N.V's Cash from Investing Activities (Yearly) stood at -$14,843 in 2020, then slumped by 61.69% to -$24,000 in 2021, then slumped by 820.83% to -$221,000 in 2022, then spiked by 89.14% to -$24,000 in 2023, then slumped by 261,766.67% to -$62.8 million in 2024.